Biologics and other novel approaches as new therapeutic options in myasthenia gravis: A view to the future

Annals of the New York Academy of Sciences

Volumn 1274, Issue 1, 2012, Pages 1-8

  Dalakas, Marinos C ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Immunobiologic therapies; Immunotherapy; Monoclonal antibodies; Myasthenia gravis

Indexed keywords

ABATACEPT; AFLIBERCEPT; ALEFACEPT; ALEMTUZUMAB; APRIL PROTEIN; AZATHIOPRINE; B CELL ACTIVATING FACTOR; BIOLOGICAL PRODUCT; CD20 ANTIBODY; CHOLINERGIC RECEPTOR; CYCLOSPORIN; DACLIZUMAB; ECULIZUMAB; EFALIZUMAB; EPITOPE; ETANERCEPT; FC RECEPTOR; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 6; JANUS KINASE 1; JANUS KINASE 3; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RILONACEPT; RITUXIMAB; TACROLIMUS; UNINDEXED DRUG;

ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL ADHESION; CELL MIGRATION; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; IMMUNOTHERAPY; MYASTHENIA GRAVIS; NONHUMAN; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TH17 CELL;

EID: 84871291826     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06832.x     Document Type: Article

References (46)

1. Engel, A.G. 2006. Acquired autoimmune myasthenia gravis. In Myology. A.G. Engel & C. Frankni-Armstrong, Eds.: 1769-1792. McGraw-Hill. New York.
2. Drachman, D.B. 2008. Therapy of myasthenia gravis. Handb. Clin. Neurol. 91: 253-272.
3. Vincent, A. & P. Rothwell. 2004. Myasthenia gravis. Autoimmunity 37: 317-319.
4. Meriggioli, M.N. et al. 2008. Strategies for treating autoimmunity: novel insights from experimental myasthenia gravis. Ann. N.Y. Acad. Sci. 1132: 276-282.
5. Sabatos-Peyton, C.A., J. Verhagen & D.C. Wraith. 2010. Antigen-specific immunotherapy of autoimmune and allergic diseases. Curr. Opin. Immunol. 22: 609-615.
6. Sanders, D.B. & A. Evoli. 2010. Immunosuppressive therapies in myasthenia gravis. Autoimmunity 43: 428-435.
7. Dalakas, M.C. 2010. Evidence-based efficacy of intravenous immunoglogulin in human myasthenia gravis and mechanisms of action. In Myasthenia Gravis: Mechanisms of Disease and Immune intervention. Premkumar Christadoss, Ed.: 89-102. Linus Publication Inc. New York.
8. Dalakas, M.C. 2004. The use of intravenous immunoglobulin in the treatment of autoimmune neurological disorders: evidence-based indications and safety profile. Pharmacol. Therap. 102: 177-193.
9. Gajdos, P., S. Chevret & K. Toyka. 2008. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst. Rev. 23: CD002277.
10. Aricha R et al. 2011. Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis. J. Autoimmun. 36: 135-141.
11. Masuda, M. et al. 2010. Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients. J. Neuroimmunol. 225: 123-131.
12. Dalakas, M.C. 2011. Immunotherapy of inflammatory myopathies: practical approach and future prospects. Curr. Treat. Options Neurol. 13: 311-323.
13. Dalakas, M.C. 2006. Therapeutic targets in patients with inflammatory myopathies: present approaches and a look to the future. Neuromusc. Disord. 16: 223-236.
14. Gold, R., M.C. Dalakas & K.V. Toyka. 2003. Immunotherapy in autoimmune neuromuscular disorders. Lancet Neurol. 2: 22-32.
15. Hohlfeld, R. & M.C. Dalakas. 2003. Basic principles of immunotherapy in neurological diseases. Sem. Neurol. 23: 121-132.
16. Dalakas, M.C. 2008. Immunotherapy of myositis: issues, concerns future prospects Nature Rev. Rheumatol. 2010: 129-137.
17. Dalakas, M.C. 2011. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat. Rev. Neurol. 7: 507-517.
18. Tak, P.L. & J.R. Kalden. 2011. Advances in rheumatology: new targeted therapeutics. Arthritis Res. Ther. 25(Suppl 1): S5.
19. Peterson, E.J. & G.A. Koretsky, 1999. Signal transduction in T lymphocytes. Clin. Exp. Rheumatol. 17: 107-114.
20. Flynn, J.M. & J.C. Byrd. 2000. Campath-1H monoclonal antibody therapy. Curr. Opin. Oncol. 12: 574-581.
21. The CAMMS223 Trial Investigators. 2008. Alemtuzumab vs. interferon Beta-1a in early multiple sclerosis. N. Engl. J. Med. 359: 1786-1801.
22. Marsh, E.A. et al. 2010. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. J. Neurol. 257: 913-919.
23. Tsokos, G.C. 2011. Systemic lupus erythematosus. N. Engl. J. Med. 365: 2110-2121.
24. Wynn, D. et al. 2011. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 9: 381-390.
25. Dalakas, M.C. 2008. Inhibition of B cell, functions: implications for Neurology. Neurology 70: 2252-2260.
26. Dalakas, M.C. 2008. B cells as therapeutic targets in autoimmune neurological disorders. Nat. Clin. Pract. Neurol. 4: 557-567.
27. Ragheb, S. 2008. A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis. Arch. Neurol. 65: 1358-1362.
28. Díaz-Manera, J. et al. 2012. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 78: 189-193.
29. Maurer, M.A. et al. 2012. Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity. J. Clin. Invest. 122: 1393-1402.
30. Tüzün, E., R. Huda & P. Christadoss. 2011. Complement and cytokine based therapeutic strategies in myasthenia gravis. J. Autoimmun. 37: 136-143.
31. Basta, M. & M.C. Dalakas. 1994. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J. Clin. Invest. 94: 1729-1735.
32. Dhodapkar, K.M. et al. 2007. Selective blockade of the inhibitory Fcgamma receptor (FcgammaRIIB) in human dendritic cells and monocytes induces a type I interferon response program. J. Exp. Med. 204: 1359-1369.
33. Anthony, R.M. et al. 2008. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320: 373-376.
34. Fee, D.B. & E.J. Kasarskis. 2009. Myasthenia gravis associated with etanercept therapy. Muscle Nerve 39: 866-870.
35. Tsai, C.Y. et al. 2000. Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron 85: 207-214.
36. Papp, K.A. et al. 2012. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366: 1181-1189.
37. Leonardi, C. et al. 2012. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366: 1190-1199.
38. Mu, L. et al. 2009. Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis. Immunology 10: 1365-2567.
39. Roche, J.C. et al. 2011. Increased serum interleukin-17 levels in patients with Myasthenia gravis. Muscle Nerve 44: 278-280.
40. van Vollenhoven, R.F. et al. 2012. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 367: 508-519.
41. Fleischmann, R. et al. 2012. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N. Engl. J. Med. 367: 495-507.
42. Sandborn, W.J. et al. 2012. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N. Engl. J. Med. 367: 616-624.
43. Sheng, J.R. et al. 2008. Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia gravis. Clin. Immunol. 128: 172-180.
44. Wanda, Castro-Borrero et al. 2012 Current and emerging therapies in multiple sclerosis: a systematic review. Ther. Adv. Neurol. Disord. 5: 205-220.
45. Tradtrantip, L. et al. 2012. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann. Neurol. 71: 314-322.
46. Steinman, L. & S.S. Zamvil. 2012. Re-engineering of pathogenic aquaporin 4-specific antibodies as molecular decoys to treat neuromyelitis optica. Ann. Neurol. 71: 287-288.